Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL
Access to Cancer Care Alleviates Racial Disparities in CLL/SLL
FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM